Laboratorios Richmond SACIF
BCBA:RICH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhuzhou Hongda Electronics Corp Ltd
SZSE:300726
|
CN |
|
Aditya Birla Money Ltd
NSE:BIRLAMONEY
|
IN |
|
P
|
Pernod Ricard SA
OTC:PDRDF
|
FR |
Laboratorios Richmond SACIF
Revenue
Laboratorios Richmond SACIF
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Laboratorios Richmond SACIF
BCBA:RICH
|
Revenue
126.7B
|
CAGR 3-Years
90%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
Laboratorios Richmond SACIF
Glance View
Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
See Also
What is Laboratorios Richmond SACIF's Revenue?
Revenue
126.7B
ARS
Based on the financial report for Dec 31, 2025, Laboratorios Richmond SACIF's Revenue amounts to 126.7B ARS.
What is Laboratorios Richmond SACIF's Revenue growth rate?
Revenue CAGR 5Y
68%
Over the last year, the Revenue growth was 38%. The average annual Revenue growth rates for Laboratorios Richmond SACIF have been 90% over the past three years , 68% over the past five years .
